ST-100 may offer new approach for dry eye disease treatment
Click Here to Manage Email Alerts
WASHINGTON — A phase 2 study found that ST-100, a collagen mimetic peptide, could provide a new avenue for treatment of dry eye disease, according to a presenter at the American Society of Cataract and Refractive Surgery meeting.
Edward J. Holland, MD, said PolyCol (Stuart Therapeutics) looks to address a new therapeutic target in dry eye disease.
“PolyCol is a collagen mimetic peptide that directly repairs damaged helical collagen,” he said. “This can upregulate inflammatory modulation, epithelial cell replacement and growth, and collagen production, while downregulating the inflammatory mediators that we see in dry eye.”
Researchers conducted a randomized controlled trial comprising 160 patients with mild to severe dry eye disease. Patients were randomly assigned to receive low-dose ST-100 (20 µg/mL), high-dose ST-100 (50 µg/mL) or placebo twice daily for 28 days. A controlled adverse environment was used to screen and challenge patients during the study.
Holland said ST-100 achieved the FDA-recognized Schirmer’s responder rate at 28 days (P = .0266). Patients who received ST-100 also showed improvement in ocular discomfort, total Ocular Surface Disease Index, visual analog scale dryness, total eye fluorescein staining and total conjunctival lissamine staining.
Drug-related adverse events were rare, and the treatment was well tolerated.
Holland said the overall results were promising for ST-100.
“This suggests a positive corneal nerve function effect,” he said. “It demonstrates the need for further study of this medication.”
Collapse
Holland E. The safety and efficacy of ST-100, topical collagen mimetic peptide as a therapeutic for dry eye disease in a phase 2 human clinical trial. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.
Read more about
Click Here to Manage Email Alerts